• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by HEXO Corp.

    6/14/23 4:50:59 PM ET
    $HEXO
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $HEXO alert in real time by email
    6-K 1 d367952d6k.htm 6-K 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of June 2023

    Commission File Number: 001-38781

     

     

    HEXO Corp.

    (Translation of registrant’s name into English)

     

     

    120 chemin de la Rive

    Gatineau, Québec, Canada J8M 1V2

    (Address of principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F  ☐            Form 40-F  ☒

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

     

     

     

    EXPLANATORY NOTE

    Exhibits 99.1 and 99.2 included with this Report on Form 6-K are hereby incorporated by reference into (i) the Registration Statement on Form F-10 of HEXO Corp. and HEXO Operations Inc. (File No. 333-256131), and (ii) the Registration Statement on Form F-10 of HEXO Corp. (File No. 333-255264).

     

    Exhibit

      

    Description

    99.1    Condensed interim consolidated financial statements for the three and nine months ended April 30, 2023 and 2022
    99.2    Management’s Discussion and Analysis for the three and nine months ended April 30, 2023
    99.3    Form 52-109F2 — Certification of Interim Filings—CEO
    99.4    Form 52-109F2 — Certification of Interim Filings—CFO


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

                      HEXO Corp.
    Date: June 14, 2023               /s/ Julius Ivancsits
          Chief Financial Officer
    Get the next $HEXO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HEXO

    DatePrice TargetRatingAnalyst
    3/4/2022$1.00 → $1.25Hold → Speculative Buy
    Canaccord Genuity
    3/4/2022Hold → Speculative Buy
    Canaccord Genuity
    3/4/2022$1.20 → $0.90Neutral
    Cantor Fitzgerald
    1/27/2022$1.07 → $0.53Underperform → Hold
    Jefferies
    12/15/2021$2.00 → $0.80Neutral → Underperformer
    CIBC
    12/15/2021Neutral → Sector Underperform
    CIBC
    12/15/2021$2.10 → $1.20Neutral
    Cantor Fitzgerald
    10/29/2021$2.29 → $2.10Neutral
    Cantor Fitzgerald
    More analyst ratings

    $HEXO
    SEC Filings

    See more
    • SEC Form 15-12G filed by HEXO Corp.

      15-12G - HEXO Corp. (0001690947) (Filer)

      7/3/23 4:15:19 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 25-NSE filed by HEXO Corp.

      25-NSE - HEXO Corp. (0001690947) (Subject)

      6/22/23 5:20:40 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form F-10POS filed by HEXO Corp.

      F-10POS - HEXO Corp. (0001690947) (Filer)

      6/22/23 5:08:06 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care

    $HEXO
    Financials

    Live finance-specific insights

    See more
    • HEXO to Host Third Quarter 2023 Earnings Conference Call

      This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 2, 2022 to its short form base shelf prospectus dated May 7, 2021 and amended and restated on May 25, 2021 HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company"), a leading producer of high-quality cannabis products, announced today that it will hold an audio-only conference call on Thursday, June 15, 2023, at 10 a.m. EDT, to review its financial results for the third fiscal quarter, ended April 30, 2023. The results will be released after market close on Wednesday, June 14, 2023. Following the prepared remarks, there will be a question-and-answer session. Ch

      6/12/23 5:10:00 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • Tilray Brands Reports Third Quarter Fiscal Year 2023 Financial Results and Announces Accretive Acquisition of 100% of HEXO Corp.

      Delivered $145.6 Million in Net Revenue and 16th Consecutive Quarter of Positive Adjusted EBITDA Maintained #1 Cannabis Market Share Position in Canada, the Largest Federally Legal Cannabis Market in the World; With HEXO Transaction, Poised to Substantially Increase Canadian Revenue Medical Cannabis Leader in Europe Achieved Key Efficiency Milestones on Accelerated Path to Positive Cash Flow, Company Reiterates Cash Flow Guidance LEAMINGTON, Ontario and NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) --  Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide commun

      4/10/23 4:15:00 PM ET
      $HEXO
      $TLRY
      Pharmaceuticals and Biotechnology
      Health Care
      Medicinal Chemicals and Botanical Products
    • HEXO to Host Second Quarter 2023 Earnings Conference Call

      This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 2, 2022 to its short form base shelf prospectus dated May 7, 2021 and amended and restated on May 25, 2021 HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company"), a leading producer of high-quality cannabis products, announced today that it will hold an audio only conference call on March 17, 2023, at 10 a.m. EDT, to review its financial results for the second fiscal quarter, ended January 31, 2023. The results will be released after market close on Thursday, March 16, 2023. Following the prepared remarks, there will be a question-and-answer session. Charlie Bo

      3/14/23 7:00:00 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care

    $HEXO
    Leadership Updates

    Live Leadership Updates

    See more
    • HEXO Announces Election of Directors

      HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO"), a leading producer of high-quality cannabis products, today announced that at the annual general meeting of shareholders held on January 31, 2023 (the "Meeting"), each of the eight director nominees was elected as a director of HEXO. Detailed results of the vote are set out below. Nominee Votes For Votes Withheld Total Votes Cast Percentage of Votes For Percentage of Votes Withheld Mark Attanasio 2,063,211 434,874 2,498,058 82.592% 17.408% Vincent Chiara 1,983,425 514,662 2,498,087 79.398% 20.602% Denise Faltischek 2,072,889 425,198 2,498,087 82.979% 17.021% Hélène

      1/31/23 5:30:00 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • HEXO Announces Leadership Transition; Company Appoints Charlie Bowman as Chief Executive Officer and Julius Ivancsits as Chief Financial Officer

      Scott Cooper Steps Down; Board of Directors Acknowledge Cooper in Stabilizing the Company Bowman and Ivancsits to Lead HEXO's Continued Transformation and Growth GATINEAU, Quebec, April 29, 2022 (GLOBE NEWSWIRE) -- HEXO Corp ("HEXO" or the "Company") (TSX:HEXO, NASDAQ:HEXO) today announced that Charlie Bowman has been appointed the Company's acting President and Chief Executive Officer, effective today. Mr. Bowman will move into a permanent role upon the successful completion of Health Canada's security clearance process for key personnel, which has been initiated. Concurrently, Scott Cooper is stepping down from his role as HEXO's President and Chief Executive Officer. "I am honoured t

      4/29/22 9:00:00 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • HEXO Announces the Appointment of a New Board Member and Acting CFO

      This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 11, 2021 to its short form base shelf prospectus dated May 7, 2021 and amended and restated on May 25, 2021. GATINEAU, Quebec, Jan. 05, 2022 (GLOBE NEWSWIRE) -- HEXO Corp ("HEXO", or the "Company") (TSX:HEXO, NASDAQ:HEXO), today announced the appointment of William Todd Montour to the Company's Board of Directors following the resignation of Jason Ewart, effective immediately. "I am pleased to welcome Will to the Board, and I am confident that his experience in cannabis operations and commercialization will be invaluable to the Company as we enter our next stage of

      1/5/22 8:05:00 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care

    $HEXO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HEXO Corp. Announces Completion of Acquisition by Way of Arrangement With Tilray Brands, Inc.

      HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company") announced today the closing of the second of two tranches of the non-brokered private placement of Series 1 Preferred Shares (the "Private Placement") previously announced on June 1, 2023 and the subsequent completion of the transactions contemplated by the previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Arrangement") involving the Company and Tilray Brands, Inc. ("Tilray"). "On behalf of HEXO's board and management team, I'd like to extend our deepest thanks to the entire HEXO team for their continued commitment to our business and customers," said Charlie Bow

      6/22/23 5:02:00 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • HEXO Corp. Announces Receipt of Final Order for Arrangement With Tilray Brands, Inc.

      HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company") announced today that the Ontario Superior Court of Justice (Commercial List) (the "Court") has granted the final order (the "Final Order") in connection with the previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Arrangement"), pursuant to which Tilray Brands, Inc. ("Tilray") will acquire all of the issued and outstanding common shares (the "Common Shares") and non-voting Series 1 Preferred Shares of the Company. Holders of Common Shares of the Company (the "Common Shareholders") will receive 0.4352 of a share of Tilray common stock (the "Tilray Shares") for each w

      6/19/23 4:06:00 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • HEXO Reports Q3'23 Financial Results

      HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company"), a leading producer of high-quality cannabis products, today reported its financial results for the third quarter of the 2023 fiscal year ("Q3'23"). All currency amounts are stated in Canadian dollars unless otherwise noted. "In the third quarter, we entered into a definitive arrangement agreement whereby Tilray will acquire all outstanding shares of HEXO," said Charlie Bowman, President and Chief Executive Officer of HEXO. "We continue to expect the transaction will be completed by June 30, 2023." "HEXO recorded $21.6 million in net revenues in the third quarter, representing an 11% decline from the second quarter," noted Jul

      6/14/23 4:51:00 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care

    $HEXO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by HEXO Corp. (Amendment)

      SC 13G/A - HEXO Corp. (0001690947) (Subject)

      2/8/23 3:28:12 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13G filed by HEXO Corp.

      SC 13G - HEXO Corp. (0001690947) (Subject)

      2/8/22 3:16:31 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13G/A filed by HEXO Corp. (Amendment)

      SC 13G/A - HEXO Corp. (0001690947) (Subject)

      11/16/21 8:34:29 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care

    $HEXO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HEXO upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded HEXO from Hold to Speculative Buy and set a new price target of $1.25 from $1.00 previously

      3/4/22 8:45:54 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • HEXO upgraded by Canaccord Genuity

      Canaccord Genuity upgraded HEXO from Hold to Speculative Buy

      3/4/22 7:41:12 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • Cantor Fitzgerald reiterated coverage on HEXO with a new price target

      Cantor Fitzgerald reiterated coverage of HEXO with a rating of Neutral and set a new price target of $0.90 from $1.20 previously

      3/4/22 6:18:18 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care